Solid Forms of CFTR Modulator for Cystic Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly those targeting the CFTR protein, face challenges in stabilizing and delivering effective pharmaceutical forms that can modulate CFTR activity, leading to inadequate therapeutic outcomes due to issues with protein folding and trafficking defects.
Innovation Solution
Development of solid polymorphic forms of the compound 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, including solvated and salt forms, which are designed to enhance solubility, absorption, and stability, facilitating their use in pharmaceutical compositions for treating CFTR-mediated diseases like cystic fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical forms are used to deliver CFTR modulators, then the basic therapeutic function is achieved, but the drug stability and bioavailability are insufficient leading to inadequate therapeutic outcomes
Solution Approach 1:
The patent applies parameter changes by developing multiple solid state forms (crystalline forms, amorphous forms, solvates, and salts) of the CFTR modulator compound. Each solid state form represents a different physical parameter configuration that improves drug stability while maintaining therapeutic efficacy. The crystalline forms provide enhanced stability through ordered molecular packing, while solvates and salts offer improved solubility and bioavailability, collectively resolving the contradiction between stability and therapeutic outcome.
Solution Approach 2:
The patent employs composite materials by creating solvate forms where the active pharmaceutical ingredient is combined with solvent molecules in a defined stoichiometric ratio within the crystal lattice. These solvate complexes (e.g., with water, ethanol, or isopropanol) represent composite material structures that simultaneously improve both stability and bioavailability properties, addressing the therapeutic outcome challenge.
2Ease of operation
If the compound is formulated to enhance solubility and absorption, then bioavailability improves, but the complexity of solid form development increases
Solution Approach 1:
The patent applies segmentation by dividing the solid form development into distinct, systematically characterized categories: crystalline forms (Forms I-X), amorphous forms, solvates, and salts. Each category is independently optimized for specific properties such as solubility, stability, or manufacturability. This segmented approach allows selection of the most appropriate solid form for enhancing absorption without requiring development of all possible forms, thereby managing complexity.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying physical parameters (crystalline structure, solvation state, salt form) to optimize absorption characteristics. Each solid state form represents a different parameter configuration that can be selected based on the desired absorption profile, allowing tailored optimization without excessive complexity.
3Reliability
If multiple solid state forms are developed to optimize therapeutic properties, then drug performance improves, but the manufacturing and characterization processes become more complex
Solution Approach 1:
The patent applies preliminary action by providing comprehensive characterization data for each solid state form (XRPD patterns, DSC thermograms, solubility profiles, stability data) before manufacturing. This pre-characterization allows manufacturers to select the most suitable form and optimize processing parameters in advance, simplifying actual manufacturing operations while maintaining high drug performance.
Solution Approach 2:
The patent manages manufacturing complexity through parameter changes by establishing clear physical and chemical parameters that define each solid state form. These well-defined parameters (crystal structure, solubility, stability characteristics) serve as manufacturing specifications that guide process optimization and quality control, making it easier to manufacture high-performance drugs despite the variety of available forms.
Data Source
AI summary
The present invention relates to a substantially a solid form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1, Solvate Form A and Compound 1, HCl Salt Form A), processes for making such forms, pharmaceutical compositions thereof, and methods of treatment therewith.